Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
43.36
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat
February 02, 2024
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
February 02, 2024
From
Bristol Myers Squibb
Via
Business Wire
Earnings Scheduled For February 2, 2024
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
Bristol-Myers Squibb's Earnings Outlook
February 01, 2024
Via
Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Amazon, Apple And 3 Stocks To Watch Heading Into Friday
February 02, 2024
With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
BMY Stock Dividend Delight: A Blue-Chip’s Healthy Yield
January 31, 2024
In the grand theater of the financial markets, Bristol-Myers Squibb stands out as a robust performer. Despite the recent pullback, the market sentiment towards this biopharmaceutical titan remains...
Via
Talk Markets
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Is Bristol Myers Squibb Stock a Buy Now?
January 25, 2024
This healthcare stock has seen healthier days.
Via
The Motley Fool
Uncovering Dividend Opportunities with NYSE:BMY.
January 25, 2024
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.
Via
Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 30, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
January 30, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
January 30, 2024
From
Bristol Myers Squibb
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
Via
Get News
Exposures
Product Safety
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.
Via
Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
--News Direct--
Via
News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...
Via
TheNewswire.com
Exposures
Product Safety
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
January 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
January 26, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
January 26, 2024
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.
Via
InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
January 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
Via
Benzinga
Exposures
Product Safety
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
January 23, 2024
Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box.
Via
InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
January 23, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...
Via
Benzinga
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
56
57
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.